Navigation Links
BIDMC scientists receive Challenge Awards from Prostate Cancer Foundation
Date:8/9/2011

221.10.254.64

BOSTON Beth Israel Deaconess Medical Center (BIDMC) researchers Martin Sanda, MD, and Steven Balk MD, PhD, have been awarded Challenge Awards of $1 million each from the Prostate Cancer Foundation (PCF) to lead two cross-disciplinary teams of investigators in their pursuit of new treatments for patients with advanced prostate cancer. The PCF Challenge Awards will support a total of 10 scientific projects nationwide; BIDMC is the only institution to receive funding for two projects.

Said PCF executive vice president and chief science officer Howard Soule, PhD, "With reductions in federal funding for prostate cancer research, it's imperative for the PCF to seek the most promising research ideas and fund them with the goal of changing clinical practice and improving outcomes for patients with advanced prostate cancer."

The research team assembled by Sanda, Director of the Prostate Cancer Program at BIDMC and Associate Professor of Surgery/Urology at Harvard Medical School, is combining nanotechnology and cancer immunology expertise in developing a vaccine to treat prostate cancer by boosting patients' immune systems.

"Recent progress has shown that cancer vaccines extend survival for men with prostate cancer and this type of treatment has now been approved by the U.S. Food and Drug Administration," explains Sanda. "However, this first-generation prostate cancer vaccine is exceedingly expensive, and the cumbersome processing of individual patient cells limits availability. Our strategy, which makes use of biodegradable nanoparticles to directly deliver prostate-cancer proteins to the body's requisite immune cells, will stimulate the immune system to directly attack prostate-cancer cells and, therefore, has the potential to be less expensive and more easily disseminated."

Sanda's Prostate Cancer Nanoparticle Vaccine Consortium is co-led by M. Simon Arredouani, PhD, of BIDMC's Department of Surgery; Joseph DeSimone, PhD, of the University of North Carolina Department of Chemistry, and Charles Drake, MD, PhD, of the Johns Hopkins Sidney Kimmell Cancer Center.

"Our work represents a synergistic collaboration that brings together some of the best doctors and scientists in the fields of prostate cancer, nanotechnology, and cancer immunotherapy across three separate leading hospitals," adds Sanda. "Such collaborative team science is the cornerstone for continued progress in developing effective new cancer therapies."

In the second of BIDMC's PCF Challenge Awards, a scientific team led by Steven Balk, MD, PhD, an investigator in BIDMC's Division of Hematology/Oncology and Professor of Medicine at Harvard Medical School, will work on research to identify and exploit mechanisms of response and resistance to therapeutics directed at the androgen receptor pathway.

"We hope to learn why patients invariably become resistant to Abiraterone acetate, a treatment used in advanced prostate-cancer cases following chemotherapy," says Balk. "If we can determine the reasons why this treatment eventually stops working, we will be better equipped to design more effective and targeted therapy for metastatic treatment-resistant disease, the lethal stage of prostate cancer responsible for approximately 30,000 deaths per year."


'/>"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
Source:Eurekalert

Related medicine news :

1. BIDMC to co-lead NIH consortium for AIDS vaccine research in nonhuman primates
2. BIDMCs Peter Weller, M.D., receives NIH MERIT Award
3. BIDMC neurologist Bernard Chang, M.D., receives award for epilepsy research
4. BIDMC investigator to receive vascular biology award from the American Heart Association
5. BIDMC researcher receives Young Investigator Award from Prostate Cancer Foundation
6. Scientists Take Navel-Gazing to New Level
7. Johns Hopkins scientists map genes for common form of brain cancer
8. Scientists May Have Found Missing Link to Common Brain Cancer
9. Have we met before? Scientists show why the brain has the answer
10. Scientists Warn of New Multidrug-Resistant Salmonella
11. Johns Hopkins scientists begin first-of-its-kind research to create blood platelets from stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... ... named Ajdin Camaga as a vice president of sales. , “Ajdin understands that ... “He works hard to understand what each client needs, and is persistent in ...
(Date:12/6/2016)... ... December 06, 2016 , ... Mount Sinai Health System today ... of Neurosurgery, where clinicians can confer and order 3D models for their cases. ... basis with quick turnaround times. This resource will be the first of its ...
(Date:12/6/2016)... ... 2016 , ... In anticipation for the New Year, Dr. Mayoor Patel has ... courses in 2017, dentists of all levels can continue to advance the services offered ... attend a variety of continuing education courses each month on topics ranging from sleep ...
(Date:12/6/2016)... ON (PRWEB) , ... December 06, 2016 , ... CarriersEdge, ... today announced a new suite of Driver Wellness courses. Offered in three modules, the ... a starting point so fleets can educate drivers about how to stay healthy on ...
(Date:12/6/2016)... Baltimore, Maryland (PRWEB) , ... December 06, 2016 ... ... Agency (HASA), including 22 as its Executive Director, Susan Glasgow has announced ... Susan’s leadership, HASA has grown to annually serve more than 4,000 individuals and ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... 6, 2016 Eurofins Genomics today announced ... College of American Pathologists (CAP) and certification under ... new laboratory in Louisville, KY ... American headquarters. "Our new CLIA-licensed and ... is still considered the ,Gold Standard, method for ...
(Date:12/6/2016)... Dec. 6, 2016 Two new disaster drones ... a simulated mass casualty event Tuesday at John Bell ... technology debuted before an audience including Mississippi ... from Homeland Security, Federal Law Enforcement Agencies, and the ... as HiRO (Health Integrated Rescue Operations), was developed by ...
(Date:12/6/2016)... 6, 2016  Arcturus Therapeutics, Inc. ("Arcturus" or ... today that it entered into collaboration with Takeda ... the treatment of NASH and other gastrointestinal (GI) ... LUNAR™ and UNA Oligomer chemistry. The financial terms ... commitment to and expertise in GI disorders, we ...
Breaking Medicine Technology: